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FDA safety communications related to highly prescribed prod-
ucts including the thiazolidinediones and bisphosphonates in
2007, information on drug safety was present weekly, if not
daily, in the newspaper and on television. To assist consumers in
understanding their risk of developing serious side effects and put
into context the relative risk of their various medications, we
have developed a 5-color drug risk rating system. METHODS:
The iGuard Risk Rating system is a patented process for sum-
marizing serious adverse events contained in each medication’s
Prescribing Information. Speciﬁcally, we focus on: 1) the severity
of the reaction (serious disability or death); 2) the likelihood of
the reaction (e.g., >1 in 10,000); and 3) proportion of the popu-
lation affected (e.g., 0–15%). We also adjust for lack of experi-
ence with a product on the market: <1,000,000 prescriptions or
<2 years post-launch. Our iGuard Risk Ratings, from lowest to
highest, are as follows: 1) Green: Low Risk–Suitable for wide-
spread use; 2) Blue: General Risk–Use under normal care of a
doctor; 3) Yellow: Guarded–Be on the lookout for safety events;
4) Orange: Elevated Risk–Create a personal risk reduction plan
with your doctor; and 5) Red: High Risk–Requires careful con-
sideration of risk versus beneﬁt. RESULTS: To date, we have
rated 106 medications. Risk Ratings associated with individual
medications are available on the project website at www.i-
guard.org. A total of 80 of 106 medications (75%) were rated
Level 2/Blue: General Risk. An additional 20% were rated Level
4/Orange: Elevated Risk. Ratings across molecules within a
therapeutic class are very similar. CONCLUSION: Consumer
feedback on the iGuard Risk Ratings has been very positive,
especially in understanding which of their medications they need
to be most diligent in monitoring.
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OBJECTIVE: Ethnic disparities in hospital discharges against
medical advice (AMA) have been examined in previous studies.
However, the institutional factors affecting health decision
making have received much less attention. This study examines
the evidence for a joint impact of ethnicity and hospital quality
on the likelihood of a discharge AMA in patients with cardio-
vascular disease (CVD). METHODS: Adult patients hospitalized
with a primary admissions diagnosis of CVD from 2000 to 2005
were identiﬁed in a state-wide conﬁdential inpatient hospital
discharge dataset. The dataset was augmented with information
from several sources, including the Joint Commission on
Accreditation of Healthcare Organizations (JCAHO). A high
quality hospital was deﬁned as a hospital whose performance
exceeded the state average on each JCAHO hospital performance
measure. A hierarchical generalized linear logistic model of a
discharge against medical advice controlling for various indi-
vidual and contextual factors was estimated using cross-sectional
data. RESULTS: A total of 2593 of the 328,342 hospitalizations
for CVD (0.8%) resulted in a discharge AMA. The patients
self-identiﬁed as non-caucasian in thirty percent (N = 100,074)
of the hospitalizations. Fifteen percent (N = 48,177) of the hos-
pitalizations occurred in high quality hospitals. The adjusted
odds of a discharge AMA in a low quality hospital were lower for
non-Caucasians (OR = 0.74; p = 0.0005) compared to Cauca-
sians while the adjusted odds of a discharge AMA in a high
quality hospital were unchanged between Caucasians and
non-Caucasians (OR = 0.95; p = 0.6). Among Caucasians, a dis-
charge AMA was less likely (OR = 0.75; p = 0.01) at a high
quality hospital compared to a low quality hospital while, among
non-Caucasians, the odds of a discharge AMA were unchanged
(OR = 0.96; p = 0.74) across hospital quality groups. CONCLU-
SION: The two unique and complementary ﬁndings here are
that: 1) institutional quality mediates the relationship between
ethnicity and hospital discharges AMA; and 2) the relationship
between hospital quality and discharges AMA varies with
ethnicity.
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OBJECTIVE: Spending on direct-to-consumer advertising
(DTCA) has seen exponential growth since the late 1990s. The
purpose of this research was to assess the association between
DTCA spending and drug utilization and reimbursement in
the U.S. Medicaid market. METHODS: National direct-to-
consumer advertising expenditures were obtained from Advertis-
ing Age for selected brands in three drug classes: HMG Co-A
reductase inhibiting agents (statins), anti-ulcer/GERD medica-
tions, and antidepressants. The drug utilization and reimburse-
ment (sales) data were extracted from the national Medicaid
pharmacy ﬁles provided by the Centers for Medicare & Medicaid
Services. The annual advertising expenditures, drug utilization,
and reimbursement were charted from 2000 to 2005. Correla-
tion analysis was used to assess the association between both
contemporaneous and lagged DTCA spending by pharmaceutical
companies and drug utilization and reimbursement for each of
the three therapeutic classes. RESULTS: A wide range of esti-
mated Pearson correlation coefﬁcients were derived, including
some negative coefﬁcients. The strongest positive correlations
were found for the statins and antidepressants for the year 2003.
Only antidepressants had a statistically signiﬁcant correlation
(r = 0.58, p < 0.05) between DTCA and reimbursement/
utilization based on a pooled correlation analysis from 2000 to
2005. CONCLUSION: Utilization rates and reimbursement in
the Medicaid market for the investigated medications were not
consistently statistically impacted by DTCA. While there is evi-
dence of a strong correlation for antidepressants, there is less
compelling evidence for statins, and none for the anti-ulcer
drugs. Although both utilization and expenditures in Medicaid
were growing for all three classes, their growth was due to
factors beyond DTCA.
HEALTH CARE USE & POLICY STUDIES—
Drug or Devices & Health Policy
PHP13
CONTROLLED SUBSTANCEWASTE IN HOME HOSPICE
SETTINGS
Maxwell T1,Woods CJ1, Steward K1, Knowlton M1, Liao D2
1excelleRx, Inc, Philadelphia, PA, USA, 2Jefferson Medical College,
Philadelphia, PA, USA
OBJECTIVE: To describe the amount and types of unused con-
trolled substances (CS) at the time of death in home hospice and
to describe methods used by hospice nurses to destroy CS after
A32 Abstracts
patients expire. METHODS: Retrospective chart review of 105
home hospice patients with a narcotic waste destruction record
who expired during a 3-month period in 2007 while receiving
care from 4 small hospices (average daily census [ADC] <60) and
1 large (ADC = 160) hospice in the Southeastern Pennsylvania
region. Data were collected through review of narcotic waste
destruction records as recorded by nurses at the time of patient
death. Strength of formulation was recorded sporadically.
Hospice nurses were surveyed about CS disposal methods.
RESULTS: Mean age of the patients was 78, (range 44–103);
majority (57%) was diagnosed with cancer, followed by heart
failure (24%). Average length of stay in hospice was 42 days
(median 21). Almost all patients had unused CS; morphine con-
centrate (20 mg/ml) was the most common medication (average
31.8 ml./patient). Collectively, over 3 liters (64,680 mg) of mor-
phine were destroyed. Lorazepam was the next most common
drug with 990 tablets and 397 ml liquid wasted. Other CS
remaining at the time of death included varying strengths of
long-acting morphine (251 tablets); OxyContin (90 tablets); and
unused transdermal fentanyl (57 patches). Hospice nurses dis-
posed of all unused CS by ﬂushing them down the toilet. CON-
CLUSION: Although not excessive on an individual level, the
amount of CS waste in hospice is signiﬁcant when viewed in the
aggregate. When ﬂushed, these medications reach water ways,
potentially posing environmental or health hazards. Regulatory
changes are required to address disposal of unused CS. Future
analyses should examine the cost of CS medication waste in
hospice.
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OBJECTIVE: The estimation of budget impact is important in
listing a new drug, but there are a lot of uncertainties. We
analyzed usage of new drug after reimbursement and investigated
various factors inﬂuencing budget impacts of the new drug to get
a guidance for public insurance BIA in Korea. METHODS: We
used 3 year claims data of 23 new drugs listed in 2004 to analyze
usage pattern and market share. We evaluated inﬂuencing factors
that clinical improvements, treatment cost, disease burden,
patient number, market competition, type of company, etc. and
conducted multiple regression analysis using these factors.
RESULTS: The indications of the 23 listing drugs were for
cancer, hypercholesterolemia, diabetes, schizophrenia, pneumo-
nia, peptic ulcer, rheumatoid arthritis, hepatitis B, HIV treat-
ment, etc. At third year after new drug listing, average market
share incrementally rose to 20% (0.06–78%, range) both in
patient number and volume of use. In case of the new drug with
clinical improve and higher cost, the average market share
amounted to 33% (n = 4). The market share of drugs with no
improve and lower costs amounted to 26% (n = 8). When total
patient number of new and pre-listed drugs were under 50,000,
market share of new drugs amounted to 25%, 35% of total
volume and patient number, respectively. But in case of over
250,000 of patients, market share of new drugs were less than
10% in both. New drugs commanded 27%, 4%, 0.08% of
market when number of pre-listed competing drugs were <25,
5–25, 25<, respectively. When the company is domestic, new
drugs amounted to about 4% of market share and 25% when it
is not. CONCLUSION: Clinical improvements, disease burden,
number of patients, number of pre-listed drug, and company type
may affect to market diffusion of new drugs. So we suggest these
results be considered in forecasting future usage of new drug and
conducting budget impact analysis.
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OBJECTIVE: The U.S. intellectual property regulations allow for
claiming the right of priority by an inventor by ﬁling a patent in
a foreign country or by ﬁling a U.S. provisional patent. The study
evaluated the provisional patent system introduced in 1994 by
the Uruguay Round Agreement Act (URAA). METHODS: Data
on patents listed in the FDA Orange Book (OB) for new chemical
entities approved between 1980 and 2007 were derived from the
USPTO. Descriptive statistics were calculated for the variables
included in the study. Chi-square and t-tests were used to assess
differences between groups. RESULTS: The OB listed 1452
patents, of which 9.6% claimed priority from a U.S. provisional
patent and 39.5% claimed priority from a foreign priority ﬁling.
The mean time gained was 328.9  75.2 days from provisional
patents and 340.8  60.3 days from foreign rights of priority.
The proportion of U.S. companies that obtained a foreign or
provisional right of priority increased from 27.4% prior to 1995
to 75.2% after 1995 (p < 0.001). This increase was due to the use
of provisional patents. A signiﬁcant increase in the use of provi-
sional patents and a signiﬁcant decrease in the use of foreign right
of priority also occurred in non-US companies, nevertheless, no
increase in the combined use of a foreign and provisional right of
priority was found for non-US companies. CONCLUSION: The
foreign companies signiﬁcantly decreased the use of foreign pri-
ority patents while increasing the use of provisional patents. The
introduction of provisional patents to the existing foreign prior-
ity system resulted in a three-fold increase in the use of these
systems by U.S. companies. The 1995 URAA change in the
USPTO priority system has signiﬁcantly inﬂuenced the frequency
by which U.S. companies seek a foreign or a provisional right of
priority.
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OBJECTIVE: The British Parliament recently held an inquiry
into the National Institute for Health and Clinical Excellence
(NICE) health technology appraisal (HTA) process. We summa-
rized stakeholder concerns about health economic and decision
methodology used for HTAs appraisals and funding decisions,
particularly with regard to serious/life-threatening illnesses,
and drew comparisons to standards among other nations that
use HTA to understand why criticisms might have arisen.
METHODS: A systematic review was conducted of written evi-
dence submitted to Parliament about the appraisal process and
corresponding health economic methods. Stakeholders were
limited to manufacturers, professional and trade associations,
and patient/disease advocacy organizations (limited to oncol-
ogy). We excluded evidence from individuals. We extracted
themes from this evidence and generated items for a comparison
of methods of other countries that conduct appraisals. Only
publicly available, English-language qualitative data were con-
sidered. RESULTS: We identiﬁed written evidence from 92
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